GlassScriptPhysician profile
Catherine Garfunkel
NPI 1275155517
$5,851.35
in general payments reported to CMS, 2019-2025
33 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $598 · 2022: $645 · 2023: $1,345 · 2024: $1,653 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,481 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,481.10 |
| Education | $126.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,014.76 | 2022-2025 | |
| Janssen Biotech, INC. | $506.10 | 2022-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $408.21 | 2022-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $315.19 | 2022-2025 | Dupixent |
| Genzyme Corporation | $257.13 | 2024-2025 | |
| Braintree Laboratories, INC. | $251.94 | 2023-2025 | Sutab, Suflave |
| Ardelyx, INC. | $211.63 | 2023-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $191.54 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $184.90 | 2022-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $148.15 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $136.40 | 2021-2025 | |
| Amgen INC. | $124.68 | 2021 | |
| Intercept Pharmaceuticals, INC. | $116.38 | 2022-2025 | |
| Boston Scientific Corporation | $105.52 | 2024 | |
| Pfizer INC. | $97.47 | 2023-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $94.74 | 2022-2025 | Linzess |
| Alnylam Pharmaceuticals INC. | $89.75 | 2021 | |
| Evoke Pharma, INC. | $75.74 | 2023-2025 | Gimoti |
| Merck Sharp & Dohme LLC | $65.40 | 2021 | |
| Qol Medical, LLC | $59.53 | 2025 | Sucraid |
| Aimmune Therapeutics, INC. | $58.56 | 2024-2025 | Zenpep |
| Celgene Corporation | $55.35 | 2023 | Zeposia |
| Gilead Sciences, INC. | $48.98 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.08 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $31.15 | 2021 | |
| Celltrion USA INC. | $27.47 | 2025 | Vegzelma |
| Axonics, INC. | $27.13 | 2024 | Axonics |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.08 | 2021 | |
| Vivus LLC | $17.92 | 2025 | Pancreaze |
| Redhill Biopharma INC. | $17.76 | 2022 | |
| Organon LLC | $17.50 | 2022 | |
| Novo Nordisk INC | $17.40 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $15.81 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Garfunkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.